Heparin-induced hyperkalemia is reversible upon drug discontinuation. Aldosterone production typically recovers within days to weeks after stopping heparin. However, unrecognized severe hyperkalemia can lead to cardiac arrest and death. Therefore, awareness and monitoring are critical, particularly in hospitalized patients receiving therapeutic-dose heparin.
Heparin-Induced Hyperkalemia: Mechanisms, Risk Factors, and Clinical Implications heparin cause hyperkalemia
Heparin-induced hyperkalemia usually develops after initiation of therapy, though it can occur as early as 48 hours in susceptible individuals. The rise in serum potassium is generally modest (0.5–1.5 mEq/L above baseline), but increases of >6.0 mEq/L have been reported. Many patients remain asymptomatic, with hyperkalemia detected only on routine laboratory monitoring. When symptoms occur, they are nonspecific and include fatigue, palpitations, nausea, and muscle weakness. Electrocardiographic changes (peaked T waves, widened QRS, bradycardia, and eventually ventricular fibrillation or asystole) may appear at potassium levels above 6.5 mEq/L. routine electrolyte monitoring
Heparin is a common cause of acquired hyperkalemia through reversible inhibition of aldosterone synthesis. While often mild, the condition can become dangerous in patients with renal impairment, diabetes, or concurrent use of potassium-modifying drugs. Early recognition, routine electrolyte monitoring, and prompt adjustment of therapy are essential to prevent complications. Clinicians should maintain a high index of suspicion for heparin-induced hyperkalemia whenever serum potassium rises unexpectedly during anticoagulation, and consider alternative anticoagulants in high-risk individuals. By understanding this electrolyte disturbance, healthcare providers can safely harness heparin’s lifesaving benefits while minimizing its metabolic risks. Many patients remain asymptomatic